All references to non-GAAP are reconciled with the most directly comparable GAAP financial measures in our earnings press release and slide presentation, which has been posted on the investors page of the company's website. ACADIA delivered a solid start to the year with total revenue of $268 million in the first quarter, representing 11% year-over-year growth on an adjusted basis. DAYBUE had an especially strong quarter with sales of $101 million, up an impressive 20%, our highest year-over-year growth since the third quarter of 2024, marking an excellent start to the year. Importantly, we saw double-digit referral growth in the first quarter and robust demand growth at 8% even prior to the expected impact of the recent sales force expansion.
I'm pleased to share that we are reaffirming our 2026 net sales guidance for both DAYBUE and NUPLAZID. Looking at our pipeline, we have several significant catalysts on the horizon. I want to remind everyone of the tremendous opportunity we have across our pipeline. Starting with DAYBUE, I'm pleased to report another excellent quarter with revenue of $101 million, representing 20% year-over-year growth.
This was another record quarter for unique patients receiving shipments, highlighting the continued momentum and durability of the DAYBUE franchise. Through Q1, we received DAYBUE STIX prescriptions for more than 250 individual patients, demonstrating strong early demand for the new formulation. Notably, nearly 30% of these patients were either treatment naive or restarting therapy, aligning with our expectations and further supporting DAYBUE's growth outlook. Collectively, this early experience demonstrates how DAYBUE STIX can help retain current patients, bring discontinued patients back into therapy, and grow the treated patient population, aligning closely with our long-term growth strategy for DAYBUE.
| Metric | Period | Current guidance |
|---|---|---|
| Total revenue | FY2026 | $1.22B-$1.28B (reaffirmed) |
| NUPLAZID net sales | FY2026 | $760M-$790M (reaffirmed) |
| DAYBUE net sales | FY2026 | $460M-$490M (reaffirmed) |
| Revenue phasing | FY2026 | Back-end loaded; greater second-half contribution from the NUPLAZID field-force ramp and broader DAYBUE STIX adoption |
| Remlifanserin ADP Phase II readout | 2026 | August-October 2026 (reaffirmed) |
| Japan trofinetide Phase III readout | 2026 | Accelerated to September-November 2026 |
| Metric | YoY | Note |
|---|---|---|
| Total revenue | +11% (adjusted) | Strong DAYBUE growth partly offset by softer NUPLAZID refills. |
| DAYBUE net sales | +20% to $101M | Highest YoY growth since Q3 2024; DAYBUE STIX uptake plus community expansion and named patient supply; gross-to-net 25.8%. |
| NUPLAZID net sales | +6% to $167M (adjusted) | ~11% referral growth and 8% demand growth offset by a temporary refill delay in January-early February; gross-to-net 22.1%. |
| R&D expense | $76.9M vs $78.3M | Roughly flat year over year. |
| SG&A expense | $171M vs $126.4M | Annualized NUPLAZID and DAYBUE field expansions and higher marketing investments. |
| Cash and investments | $851M (up from $820M) | Positive operating cash flow. |
| Topic | Previous mention | Current period | Trend |
|---|---|---|---|
| DAYBUE STIX ramp | December 2025 FDA approval; broad launch planned early Q2 | COE-focused Q1 launch drew >250 prescriptions (~30% naive/restart), >80% caregiver satisfaction, and full U.S. availability from early April; ~450-patient opportunity may be captured faster than the original three-year assumption. | — |
| NUPLAZID refill dynamics | Strong Q4 2025 momentum | A temporary Q1 refill delay (Jan-early Feb) normalized; ~11% referral and 8% demand growth support the reaffirmed full-year outlook, with field-force benefits building later in 2026. | — |
| R&D leadership transition | Stable R&D leadership | Elizabeth Thompson announced retirement by year-end; she remains fully engaged through the remlifanserin readouts and early Phase III planning while a successor is sought. | — |
| NUPLAZID demand generation | DTC campaigns launched | Renewed Ryan Reynolds 'More to Parkinson's' campaign lifted awareness of hallucinations/delusions from 8% to over 30%; 10-year FDA-approval anniversary with nearly 100,000 patients treated. | — |